ArticleBreast (Edinburgh, Scotland)2026

Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial.

Yeon Hee Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.